Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.

Taoufik AlsaadiSuzan NooriRazmig VarakianSaly YoussefAbuBaker Almadani

Published in: BMC neurology (2022)

In this real-world study on erenumab use in the UAE, patients prescribed erenumab achieved clinically meaningful reductions in MHD and MSMD at all assessed time points. Erenumab was well tolerated with no new safety events.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes